Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROMOTE-FL: Pirtobrutinib and Mosunetuzumab to Enhance Treatment Efficacy for Patients With Relapsed/Refractory Follicular Lymphoma

NCT06948786 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT06948786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06948786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROMOTE-FL: Pirtobrutinib and Mosunetuzumab to Enhance Treatment Efficacy for Patients With Relapsed/Refractory Follicular Lymphoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Recruiting
Start date
November 17, 2025
Completion date
July 31, 2031
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3a follicular lymphoma, recurrent follicular lymphoma, refractory follicular lymphoma